Altimmune, Inc. (ALT) stock
ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.61−0.32 (-16.58%)
Close on Nov 12, 2026Market cap $313.17MP/E –Yield –
Altimmune operating margin
Operating margin is operating income as a percentage of revenue.
Altimmune's operating margin for the twelve months ending Dec 31, 2025 was -230461.0%. For fiscal 2025 it was -230461.0%, against -515860.0% the year before. The highest annual figure on record is -48.3% in fiscal 2011.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -230461.0% | +285399.0 |
| FY2024 | Dec 31, 2024 | -515860.0% | −493341.5 |
| FY2023 | Dec 31, 2023 | -22518.5% | −20320.9 |
| FY2021 | Dec 31, 2021 | -2197.6% | −1528.1 |
| FY2020 | Dec 31, 2020 | -669.5% | −299.5 |
| FY2019 | Dec 31, 2019 | -370.0% | +44.6 |
| FY2018 | Dec 31, 2018 | -414.6% | +70.1 |
| FY2017 | Dec 31, 2017 | -484.7% | −141.9 |
| FY2016 | Dec 31, 2016 | -342.7% | −294.4 |
| FY2011 | Dec 31, 2011 | -48.3% | +63.9 |
| FY2010 | Dec 31, 2010 | -112.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -111126.9% | +386193.1 |
| Q3 FY2025 | Sep 30, 2025 | -417180.0% | +78160.0 |
| Q2 FY2025 | Jun 30, 2025 | -458440.0% | +76460.0 |
| Q1 FY2025 | Mar 31, 2025 | -436300.0% | +99580.0 |
| Q4 FY2024 | Dec 31, 2024 | -497320.0% | −406447.0 |
| Q3 FY2024 | Sep 30, 2024 | -495340.0% | −489113.5 |
| Q2 FY2024 | Jun 30, 2024 | -534900.0% | −234783.3 |
| Q1 FY2024 | Mar 31, 2024 | -535880.0% | −432265.7 |
| Q4 FY2023 | Dec 31, 2023 | -90873.0% | +1146727.0 |
| Q3 FY2023 | Sep 30, 2023 | -6226.5% | +248711.0 |
| Q2 FY2023 | Jun 30, 2023 | -300116.7% | −239182.3 |
| Q1 FY2023 | Mar 31, 2023 | -103614.3% | −102882.4 |
| Q3 FY2022 | Sep 30, 2022 | -1237600.0% | −1216584.8 |
| Q2 FY2022 | Jun 30, 2022 | -254937.5% | −236788.6 |
| Q1 FY2022 | Mar 31, 2022 | -60934.4% | −59161.0 |
| Q4 FY2021 | Dec 31, 2021 | -731.9% | −267.1 |
| Q3 FY2021 | Sep 30, 2021 | -21015.2% | −20391.5 |
| Q2 FY2021 | Jun 30, 2021 | -18148.9% | −15596.7 |
| Q1 FY2021 | Mar 31, 2021 | -1773.4% | −1443.2 |
| Q4 FY2020 | Dec 31, 2020 | -464.8% | +284.1 |
| Q3 FY2020 | Sep 30, 2020 | -623.7% | +1126.9 |
| Q2 FY2020 | Jun 30, 2020 | -2552.3% | −2333.9 |
| Q1 FY2020 | Mar 31, 2020 | -330.2% | −251.4 |
| Q4 FY2019 | Dec 31, 2019 | -748.9% | +307.5 |
| Q3 FY2019 | Sep 30, 2019 | -1750.6% | −1596.5 |
| Q2 FY2019 | Jun 30, 2019 | -218.4% | +6.5 |
| Q1 FY2019 | Mar 31, 2019 | -78.8% | +144.0 |
| Q4 FY2018 | Dec 31, 2018 | -1056.4% | −609.1 |
| Q3 FY2018 | Sep 30, 2018 | -154.0% | +520.0 |
| Q2 FY2018 | Jun 30, 2018 | -224.9% | −92.8 |
| Q1 FY2018 | Mar 31, 2018 | -222.8% | +1285.1 |
| Q4 FY2017 | Dec 31, 2017 | -447.3% | +61.1 |
| Q3 FY2017 | Sep 30, 2017 | -674.1% | – |
| Q2 FY2017 | Jun 30, 2017 | -132.0% | – |
| Q1 FY2017 | Mar 31, 2017 | -1507.8% | – |
| Q4 FY2016 | Dec 31, 2016 | -508.4% | – |
See a number that looks wrong?